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An episomal CRISPR/Cas9 system to derive
vector-free gene modiﬁed mammalian cells
Dear Editor,
CRISPR and CRISPR-associated (Cas) proteins play their
adaptive immunity role in degrading foreign nucleic acids in
both bacteria and archaea. CRISPR/Cas has proved efﬁ-
cient in modifying mammalian genomes (Cong et al., 2013;
Mali et al., 2013) and various delivery methods for Cas9:
gRNA complex have been established. Among different
delivery means, in vitro transcribed Cas9 mRNA/gRNA,
puriﬁed Cas9 protein, and adeno-associated virus (AAV)
driven seem promising toward clinical applications (Koura-
nova et al., 2016; Lin et al., 2014; Yin et al., 2016). Still, all
the fore-mentioned methods for delivering CRISPR/Cas9
have certain shortcomings. In vitro transcription and protein
puriﬁcation are complicated and inconvenient for use, while
AAV mediated system suffers from the side effects of
immune response and insertional mutagenesis (Donsante
et al., 2007; Li et al., 2011).
Episomal vectors based on oriP-EBNA1 have been
shown as an effective method to derive vector-free cells in
reprogramming studies (Okita et al., 2011; Yu et al., 2009).
Without selection pressure, EBV vectors are gradually lost in
each generation due to their defects in synthesizing and
partitioning thus resulting in transgene-free daughter cells
(Nanbo et al., 2007). We thus set out to test if Cas9 protein
and gRNA can be effectively delivered as episomes to
generate vector-free mutations in mammalian cells. Here we
report efﬁcient human genome editing with CRISPR/Cas9
technology in the form of oriP-EBNA1-based episomes. To
obtain oriP-EBNA1-based CRISPR/Cas9 vectors, we ﬁrst
assembled CMV-FLAG-hSpCas9-2A-GFP and U6-gRNA
and oriP-EBNA1 fragments together. To further enrich suc-
cessfully transfected cells, we added SV40-puro to form
pCRISPR-S12 (Fig. 1), which hereafter is referred to as oriP-
EBNA1-based CRISPR/Cas9 vector or system.
To test the oriP-EBNA1-based CRISPR/Cas9 system, we
ﬁrst examined its efﬁciency for disrupting single-copy tdTo-
mato expression driven by CAG promoter in mouse induced
pluripotent stem cells (miPSCs). We designed crtdTomato to
target tdTomato coding sequence with the expectation of
destructing an existing Sau3AI restriction enzyme site
(Fig. 2A). The tdTomato-tagged-miPSCs were transfected
with pCRISPR-S12-crtdTomato and manipulated according
to the ﬂowchart (Fig. 2B). We observed disappearance of
tdToamto ﬂuorescence in some of the miPSCs clones under
a ﬂuorescent microscope (Fig. 2C). Further, ﬂow-activated
cell sorting (FACS) showed a reduction of 26% tdTomato-
labeled cells in crtdTomato treated group when compared
with non-transfected group ﬁve days post transfection
(Fig. 2D). These results suggested that our system works in


















Figure 1. Circular map of oriP-EBNA1-based CRISPR/
Cas9 vector. CMV, cytomegalovirus promoter; 3× FLAG,
FLAG epitope tag; hCas9, humanized Streptococcus
pyogenes Cas9; F2A, 2A regions of foot-and-mouth
disease virus; GFP, green ﬂuorescent protein gene; BGH
pA, bovine growth hormone polyA signal; U6, human U6
promoter; chimeric gRNA, synthetic gRNA scaffold; oriP,
Epstein-Bar virus (EBV) latent origin of replication; EBNA1,
EBV nuclear antigen-1, replication transactivator of EBV;
SV40, SV40 promoter; Puro, puromycin resistant gene;
Amp, ampicillin resistant gene; pUC ori, replication origin;
TK promoter, thymidylate kinase promoter; Hygro, hygro-
mycin resistant gene; pA, polyA signal.
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Next, we further detected the targeting efﬁciency of our
system in 6 non-red (NR) single clones. We were able to
PCR amplify the target regions in 4 out of the 6 NR clones.
Clones NR4 and NR6 were not analyzed further since PCR
failed to produce products (Fig. S1). PCR products of the
remaining 4 clones were conﬁrmed as expected mutants by
restriction fragment length polymorphism (RFLP) assays
(Fig. 2E and 2F). Among these, clone NR1 showed a trun-
cated size (Fig. S1), which was further conﬁrmed by Sanger
sequencing as a 341 nucleotides deletion (Fig. 2F). Above
data showed that our oriP-EBNA1-based CRISPR/Cas9
system could mediate efﬁcient gene disruption.
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Figure 2. oriP-EBNA1-based CRISPR/Cas9 disrupted ﬂuorescent expression in miPSCs. (A) Schematic of crtdTomato targeting
site (blue arrow), primers used (purple arrows) for amplifying genomic sequences ﬂanking target sites (light gray boxes), CAG
promoter (green box) drove the expression of tdTomato (red box), and Sau3AI restriction sites were used for RFLP assay.
(B) Schematic of the experimental procedure. (C) Disappearance of red ﬂuorescence in partial tdTomato-labelled-miPSCs clones.
Scale bar, 200 μm. (D) FACS analysis of crtdTomato transfected and non-transfected miPSCs. The upper two panels are crtdTomato
transfected group (tdTomato + with a portion of 67%) and the lower two panels are non-transfected group (tdTomato+ with a portion of
93%). (E) RFLP of non-red (NR) clones by Sau3AI. The green pentagrams indicated the uncut PCR amplicons by Sau3AI. Ladder,
1 kb plus ladder in all ﬁgures in this study. (F) Sanger sequencing conﬁrmed deletion of 341 bp of NR1-d20 clone. The purple line
between G/G showed the deleted site. (G) PCR conﬁrmed the removal of EBNA1 fragment in clone NR1-d20, NR2-d20, NR5-d20 but
not in NR3-d20. pCRISPR-S12 DNA was used as positive control (“+” in all ﬁgures in this study). “wt” stands for wild type mouse
genomic DNA. Red pentagram shows visible EBNA1 residue in NR3-d20. (H) Western blot showed no hSpCas9 expression in clone
NR1-d20, NR2- d20, NR3-d20, and NR5- d20. HeLa cells expressing FLAG-hSpCas9-2A-GFP stably was used as positive control
(“+” in all ﬁgures in this study). The expected protein band is about 190 kDa.
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Finally, we examined whether these four successfully
engineered miPSCs (NR1, NR2, NR3, NR5) were free of
targeting vector. PCR analysis showed that 3 clones were
free of vectors, but clone NR2-d20 still retained residual
amount of vectors (Fig. 2G). However, Western blot of
FLAG-hSpCas9-2A-GFP further veriﬁed no continuous
expression of hSpCas9 protein of all four clones (Fig. 2H),
suggesting that PCR detection was more sensitive in
detecting foreign gene expression than Western blot assay.
Together, these results demonstrated that our oriP-EBNA1-
based CRISPR/Cas9 system inactivated reporter gene
expression as expected, and more importantly, vector-free
engineered cell lines can be readily obtained.
We further attempted to examine whether our system
works well in human cells. The basic functions of CRISPR/
Cas9 were conﬁrmed by deleting accurately more than 2 kb
intervening nucleotides of human chemokine receptor 5
(CCR5) as well as editing multiplex genes (human TET1,
TET2, and TET3) simultaneously (Figs. S3–S6 and
Table S1). Moreover, our oriP-EBNA1-based CRISPR/Cas9
system was free of vector in both genetically modiﬁed
miPSCs and human cells. Together, these results demon-
strated the feasibility of manipulating mouse and human
genomes with our oriP-EBNA1-based CRISPR/Cas9
system.
In the current study, we have veriﬁed the functionality of
our episomal CRIPSR/Cas9 system ﬁrst by inactivating vis-
ible reporter gene, and further by speciﬁcally deleting a
single genomic region and editing multiplex genes in a
transgene-free manner.
One potential risk for CRISPR/Cas9 in genome editing is
its uncertain off-target effects which could confound gen-
ome-editing-based therapies. In present study, we detected
certain frequencies (none for crTETs and 10% for crCCR5)
of off-target events by T7EI assay (Fig. S7 and Table S2). In
the future, combined with other progresses, such as mutant
Cas9 or new homologues and optimized gRNA design,
episomal CRISPR/Cas9 could further ameliorate, if not
eliminate, the off-target inﬂuences, thereby broadening its
application.
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